Nucleic acid aptamer for detecting tumor marker AFP and lateral chromatography test strip

AFP was detected through lateral chromatography strips that bind specific nucleic acid aptamers to gold nanoparticles, and the problem of high cost and slow detection of ELISA was solved, and fast and accurate detection of liver cancer markers was achieved, which improved liver cancer screening Check efficiency and accuracy.

CN118910066APending Publication Date: 2024-11-08成都医学院第一附属医院 +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411306552.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-19
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The existing AFP detection method of liver cancer marker ELISA has high cost, slow detection speed and insufficient antibody batch differences, which hinders the popularization of liver cancer screening. In addition, lateral chromatography tests lack AFP atopic antibody gold nanoparticle materials. Limits applications for rapid detection.

Method used

The specific nucleic acid apt30, apt17 or apt1 are used to bind gold nanoparticles to detect AFP for lateral chromatography test strips. The rapid and accurate detection of liver cancer markers can be achieved through atopic binding, and non-target substance interference is eliminated. , and set up complementary sequences on the detection line and the quality control line to terminate the detection.

Benefits of technology

It realizes fast, convenient and accurate AFP detection, reduces the detection cost and labor demand, and ordinary people can complete the test, and the results are obtained within 15 minutes, and the review is simple, which improves the sensitivity and specificity of early diagnosis of liver cancer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118910066A_ABST
    Figure CN118910066A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of bioengineering, and particularly relates to a nucleic acid aptamer for detecting a tumor marker AFP and a lateral chromatography test strip, the nucleic acid aptamer has sequences of apt30, apt17 and apt1, and can be used for specific detection and analysis of AFP protein. The lateral chromatography test strip applying the aptamer comprises a PVC (polyvinyl chloride) bottom plate, a sample absorption pad, a combination pad, a reaction pad and an adsorption pad, the plurality of LED chips are sequentially arranged on the PVC bottom plate and are connected with one another; the reaction pad is provided with a detection line and a quality control line; a nucleic acid aptamer gold nanoparticle compound is arranged in the combination pad, and nucleic acid aptamers apt30, apt17 and apt1 contained in the compound can be subjected to a specific reaction with a tumor marker AFP. Compared with an ELISA detection method, the lateral chromatography test strip has the advantages of high efficiency, rapidness, low cost and the like, detection can be completed by ordinary people, and a detection result can be obtained only by waiting for 15 minutes.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of bioengineering, and in particular relates to a nucleic acid aptamer and a lateral flow test strip for specifically detecting a tumor marker AFP. Background Art

[0002] The tumor marker AFP (Alpha-Fetoprotein) is a protein produced by the liver and digestive system during fetal development. In adults, serum AFP levels less than 25 ng / mL are normal, but in certain pathological conditions, such as hepatocellular carcinoma (liver cancer) and certain germ cell tumors (such as testicular cancer and ovarian cancer), AFP levels will increase to more than 400ng / mL. In addition, viral hepatitis and cirrhosis can also cause AFP levels to increase, most of which are between 20-200ng / mL.

[0003] Therefore, alpha-fetoprotein is a specific liver cancer marker. As the gold standard for HCC detection and an important marker for liver health diagnosis, it is widely used in the screening and diagnosis of liver cancer. In the existing technology, the most commonly used method for AFP detection is enzyme-linked immunosorbent assay (ELISA), which binds AFP with specific antibodies and uses enzyme-labeled secondary antibodies to detect the bound AFP. Finally, the absorbance of the enzyme reaction is measured to determine the concentration of AFP.

[0004] However, the ELISA test method has many limitations, resulting in high application costs and labor-intensive testing. First, the ELISA test method requires a variety of reagents (including antibodies, enzyme-labeled secondary antibodies, substrates, etc.), and the reagent cost is relatively high; second, professional technicians are required to operate the test process, and the addition, incubation, and washing of reagents in the ELISA test process are time-consuming. Therefore, the promotion rate of the ELISA test method in people's health check-ups is still relatively low. In addition, ELISA may also have cross-reactions, resulting in false positives, which require re-examination and cannot be conveniently checked quickly or re-examined for confirmation.

[0005] Lateral Flow Assay (LFA) is a simple, fast and inexpensive detection method. It is easy to operate, low-cost and can produce results quickly. It can be quickly tested without professionals. It is widely used in clinical diagnosis, food safety, environmental monitoring and biological science research. However, the lateral flow assay relies on the specific reaction between the antibody gold nanoparticle material and the test substance. The existing technology does not have the liver cancer tumor marker AFP specific antibody gold nanoparticle material test paper, which seriously hinders the proportion of people who screen for liver cancer tumors in routine physical examinations, and has formed a huge obstacle to the early detection and treatment of liver cancer tumors. Summary of the invention

[0006] The purpose of the present invention is to provide an aptamer and lateral flow test strip for specific detection of tumor marker AFP in view of the shortcomings of the prior art ELISA detection method for liver cancer tumor markers, such as high cost, slow detection speed, and variability between antibody batches.

[0007] In order to achieve the above-mentioned invention object, the following technical solutions are provided: A nucleic acid aptamer for specifically detecting a tumor marker AFP, wherein the sequence of the nucleic acid aptamer is at least one of apt30, apt17 or apt1.

[0008] Nucleic acid aptamers apt30, apt17, and apt1 can specifically bind to the tumor marker AFP and replace antibodies in immunohistochemistry (IHC) detection to label AFP in hepatocellular carcinoma lesions. They can be used to quickly detect the tumor marker AFP in patient serum. Specific detection of tumor marker AFP is the ability of evaluating diagnostic tools (such as nano colloidal gold test strips) to exclude interference from non-target substances when detecting specific targets (liver cancer marker AFP protein), which is one of the advantages of nano colloidal gold test strips.

[0009] Furthermore, the sequence of the nucleic acid aptamer apt30 is SEQ NO.3.

[0010] SEQ NO.3 is CCACAGTCCGGACCCCACGTTGCTACCGGCGCCGTCG.

[0011] Furthermore, the sequence of the nucleic acid aptamer apt17 is SEQ NO.2.

[0012] SEQ NO. 2 is CCAACCGCATGACGAGGCTATGGGACACTTGCCCTGCCCG.

[0013] Furthermore, the sequence of the nucleic acid aptamer apt1 is SEQ NO.1.

[0014] SEQ NO.1 is CACCCACCATACACCCTGTCCACATGCCTGACCTCATGCG.

[0015] Furthermore, the 5' end of the aptamer selected as aptamer A modified on the surface of the nanogold is connected to thymine, that is, thymine-TTT- is connected to the 5' end. Preferably, 3-10 thymines are connected.

[0016] The 5-end of the nucleic acid aptamer is connected to 3-10 thymine T (poly T), such as 3 thymine-TTT-, and then connected to gold nanoparticles (Au NP) through a thiol group to obtain a gold nanoparticle complex combined with nucleic acid aptamer A and thymine-TTT-, which is used as a binding target protein AFP and can be used to detect whether the sample contains AFP protein.

[0017] For example, three thymines were connected to the 5' end of apt30 and then combined with gold nanoparticles (Au NPs) to obtain the AuNP-aptamer apt30-poly T complex for use as a binding agent.

[0018] Taking apt30 as an example, the sequence of the aptamer bound to gold nanoparticles (Au NP) is: 5′-SH-TTT- nucleic acid aptamer apt30-3′.

[0019] Correspondingly, the quality control line (C line) is set to a fixed poly C sequence: adenine -AAAAAAAAA-. Three thymine Ts are connected to the 5' end of the aptamer to form a complementary sequence. By polymerizing 3-15 adenines, a poly A complementary sequence is formed (complementary to the poly T connected to the aptamer), such as poly A formed by 9 adenines, -AAAAAAAAA-.

[0020] Furthermore, aptamers apt30, apt17, and apt1 、 Both ends are modified with fluorescent agents.

[0021] The fluorescent agent is 6-FAM (6-carboxyfluorescein), or FITC (fluorescein 5-isothiocyanate) or TRITC (Texas Red). It can also be any one of the existing fluorescent agents. Wailian Biotech Company modifies and synthesizes the nucleic acid aptamer with the 5' end modified with the fluorescent agent.

[0022] Furthermore, the above-mentioned nucleic acid aptamer is obtained by PCR amplification and mutation of the initial library sequence SEQ NO.4 and specific screening.

[0023] Further, Primer 1 and / or Primer 2 are used in the PCR amplification process.

[0024] The sequence of primer 1 is SEQ NO.5. The sequence of primer 2 is SEQ NO.6.

[0025] Specifically, the initial library sequence SEQ NO.4 is ATCCAGAGTGACGCAGCANNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNTGGACACGGTGGCTTAGT.

[0026] The sequence of primer 1 is SEQ NO.5.

[0027] Among them, SEQ NO.5 is ACTAAGCCACCGTGTCCA.

[0028] Primer 2 sequence SEQ NO.6.

[0029] Among them, SEQ NO.6 is ATCCAGAGTGACGCAGCA.

[0030] The present invention also provides an application of a nucleic acid aptamer, and an application of a nucleic acid aptamer with a sequence of apt30, apt17 or apt1 in the preparation of a detection reagent, a test kit, and a lateral flow test paper.

[0031] Preferably, the nucleic acid aptamer having the sequence of apt30, apt17 or apt1 is used in the preparation of a reagent, a kit or a lateral flow test strip for detecting liver cancer.

[0032] A lateral flow test strip for detecting a tumor marker AFP based on aptamer specificity, the lateral flow test strip comprising a PVC bottom plate, a sample suction pad, a conjugation pad, a reaction pad and an adsorption pad; the sample suction pad, the conjugation pad, the reaction pad and the adsorption pad are sequentially arranged on the PVC bottom plate and are connected to each other without gaps; The reaction pad is provided with a detection line and a quality control line; The binding pad is provided with a gold nanoparticle complex binding to a nucleic acid aptamer A, wherein the sequence of the nucleic acid aptamer A is one of SEQ NO.1, SEQ NO.2 or SEQ NO.3; The detection line is provided with a nucleic acid aptamer B, the sequence of the nucleic acid aptamer B is selected from one of SEQ NO.1, SEQ NO.2 or SEQ NO.3, and the nucleic acid aptamer B and the nucleic acid aptamer A are different sequences.

[0033] The quality control line is provided with a complementary sequence polyadenine or anti-human immunoglobulin (IgG).

[0034] Furthermore, the polyadenine is a continuous adenine amino acid sequence, and the number of polyadenine is 5-15, such as -AAAAAAAAA-.

[0035] Among them, the complementary sequence polyadenine is a sequence complementary to the polythymine oligomer chain, which is used to connect the polythymine complementary binding at the A5′ end of the nucleic acid aptamer on the quality control line and the surface of the gold nanoparticles, terminate the detection, and complete the detection work of the test strip.

[0036] The lateral flow test strip of the present invention contains an aptamer A gold nanoparticle complex that can specifically bind to the tumor marker AFP, and can achieve rapid and specific detection of tumor markers. When the lateral flow test strip is used, the sample to be tested is dripped onto the sample suction pad. If the liver cancer target AFP protein is contained, the tumor marker AFP protein will react and firmly bind to the nucleic acid aptamer A in the sample suction pad, and together with the gold nanoparticle complex, it moves to the adsorption pad along with the sample solution. When the gold nanoparticle complex (connected with nucleic acid aptamer A) bound to the tumor marker AFP protein reaches the detection line (i.e., T line), the tumor marker AFP reacts with the nucleic acid aptamer B, and the detection is completed.

[0037] The quality control line setting (i.e., the setting of the C line) is a complementary sequence of polyadenine, which uses the complementary binding of the sequence on the nucleic acid aptamer A to the adenine sequence of the quality control line to terminate the detection, and the test strip completes the detection work.

[0038] The gold nanoparticle complex combined with nucleic acid aptamer A is obtained by the following method: First, 3-10 T bases (poly T) connected to a thiol group were modified at one end of apt17, and then the nucleic acid aptamer A-poly T was coupled to Au NP (gold nanoparticle) using the thiol group (-SH) to obtain a gold nanoparticle complex bound to the nucleic acid aptamer A.

[0039] That is, nucleic acid aptamer A is apt17, and then nucleic acid aptamer B is set to apt30.

[0040] In this way, the nucleic acid aptamer A first connects to the poly T complex, and then combines with gold nanoparticles through the thiol group to form AuNP-SH-poly T complex-aptamer apt17, which combines with AFP in the sample suction pad and flows toward the binding pad. Another nucleic acid aptamer apt30 that also has affinity for AFP is fixed on the T line to compete for the binding of AFP bound by apt17, so that the T line begins to show color, thereby completing the target protein AFP detection. The Au NP-SH-poly T complex-aptamer apt17 continues to flow to the C line, and the poly A complex poly A (poly A is 5-15 adenine A bases, preferably 9 A bases) complementary to the poly T complex (poly T) is fixed in the C line. Poly A and poly T complement each other to achieve color development of the C line, verifying that the test strip can work normally.

[0041] Compared with the ELISA detection method, the detection method of the present invention has the advantages of high efficiency, rapidity and convenience. It does not require professional operation, and ordinary people can complete the detection work. The test results can be obtained in 15 minutes. Even if a review is required, it only requires a simple operation again. By screening nucleic acid aptamer A for liver cancer target AFP, nucleic acid aptamer A is fixed on the surface of gold nanoparticles, nucleic acid aptamer B is fixed on the detection line, and samples containing AFP markers are detected using lateral flow chromatography technology.

[0042] Furthermore, the sample suction pad, the binding pad, the reaction pad and the adsorption pad are arranged in sequence, and the adjacent two are overlapped and connected. That is, the sample suction pad, the binding pad, the reaction pad and the adsorption pad are arranged in sequence on the PVC bottom plate; and the adjacent two are overlapped and connected.

[0043] Furthermore, the nucleic acid aptamer A is bound to gold nanoparticles (Au NP) by connecting the 5′ end to a polythymine linker sequence, and then connecting to a thiol group through the polythymine linker sequence, and then binding to the gold nanoparticles through the thiol group.

[0044] The polythymine linking sequence is an oligomeric chain formed by 3-10 thymines, for example, an oligomeric chain of 3 or 9 thymines, or a peptide chain formed by the polymerization of simple thymines.

[0045] Furthermore, the nucleic acid aptamer A is obtained by screening through the SELEX system of biolayer interferometry, and the sequence of the nucleic acid aptamer A is at least one of SEQ NO. 1, SEQ NO. 2, or SEQ NO. 3. The nucleic acid aptamer A is obtained through screening and has the ability to specifically bind to the AFP protein.

[0046] In brief: the target peptide AFP protein is loaded (loading 600″, loading for 600 seconds) onto the NTA sensor, the binders bound to the target are screened out from the random oligomer pool, and dissociated into different microtiter wells in turn. Each microtiter well contains a dissociation buffer with increased ionic strength according to the binding affinity (0.1-1M), such as increasing the ion concentration and using normal human serum diluted at different times, to continuously optimize the environment for aptamer screening and simulate the microenvironment of human blood as much as possible, to ensure that the selected aptamers have a higher affinity for AFP, and to improve the reliability and repeatability of the experiment. After multiple rounds of elution, the aptamers that remain on the surface of the NTA sensor and firmly bind to AFP are separated by proteinase K to degrade AFP, and then PCR amplified as the aptamer library for the next screening.

[0047] Among them, NTA, namely Ni-NTA, is the full name of nickel ion metal chelate affinity chromatography medium, which is used to fix His-tagged proteins in protein interaction detection.

[0048] Furthermore, the aptamer B is also screened by the SELEX system of biolayer interferometry. The aptamer B can form an antibody pair with the aptamer A and competitively bind to the AFP protein. When the aptamer A bound to the AFP protein reaches the detection line, it can bind to the aptamer bound to the AFP protein and develop color.

[0049] In brief: the target peptide AFP is loaded (loading 600") onto the NTA sensor, the binders bound to the target are screened out from the random oligomer pool, and dissociated into different microtiter wells in turn. Each microtiter well contains a dissociation buffer with increased ionic strength according to the binding affinity (0.1-1M), such as increasing the ion concentration and using normal human serum diluted at different times, to continuously optimize the environment for aptamer screening and simulate the microenvironment of human blood as much as possible, to ensure that the selected aptamers have a higher affinity for AFP, and to improve the reliability and repeatability of the experiment. After multiple rounds of elution, the aptamers that remain on the surface of the NTA sensor and firmly bind to AFP are degraded and separated by proteinase K, and then PCR amplified as the aptamer library for the next screening. Among them, the detection marker is AFP (alpha-fetoprotein), a biomarker that can reflect the early changes of liver cancer.

[0050] That is, the sequences of nucleic acid aptamer A and nucleic acid aptamer B are both selected from one of SEQ NO.1, SEQ NO.2 or SEQ NO.3, and nucleic acid aptamer B and nucleic acid aptamer A are different sequences.

[0051] The aptamer and thymine-TTT- with affinity for the target protein are connected to the surface of the nanogold. The detection line is set with another aptamer B with good affinity for the clear protein. The quality control line is set with the complementary sequence adenine-AAAAAAAAA-, or incubated with IgG antibodies.

[0052] Furthermore, the gold nanoparticles and the nucleic acid aptamer A are combined together to form an antibody-gold nanoparticle complex. The method for preparing the aptamer-gold nanoparticle complex is as follows: three thymines are connected to the 5' end of the nucleic acid aptamer A, and then the thymines and the gold nanoparticles are connected through the thiol group.

[0053] The antibody-gold nanoparticle complex is constructed by binding a specific aptamer with high affinity to the liver cancer marker AFP to gold nanoparticles through a thiol coupling agent. The antibody is nucleic acid aptamer A, and nucleic acid aptamer A is bound to gold nanoparticles through a thiol coupling agent to obtain an Au NP-SH-nucleic acid aptamer A-poly T complex.

[0054] Furthermore, the sample suction pad, the binding pad, the reaction pad and the adsorption pad are sequentially arranged on the PVC bottom plate, and adjacent two parts are overlapped and connected. Preferably, all adjacent overlapped parts are in the same order.

[0055] Preferably, the overlap width is 0.1-3 mm, and the distance between the detection line and the quality control line on the reaction pad is set to 3-30 mm, preferably 4-20 mm, more preferably 4-10 mm. The preferred embodiment is 6.5 mm.

[0056] The lateral flow test strip consists of four parts, each of which is selected and designed with its specific function to provide the most effective detection and analysis services.

[0057] Furthermore, the conjugate pad preparation method is: connecting the nucleic acid aptamer A to the gold nanoparticles to form a nucleic acid aptamer A-gold nanoparticle complex, and coating the nucleic acid aptamer A-gold nanoparticle complex on the conjugate pad; then, setting a detection line and a quality control line on the reaction pad.

[0058] Further, as described above, the nucleic acid aptamer A is prepared by a poly-T complex and a thiol-based nanoparticle, wherein the poly-T complex is a 3-10 thymine T oligomeric peptide chain.

[0059] Assemble in sequence and complete the connection to form a complete test strip.

[0060] Then, the test strip is optimized. The test strip optimization method includes: optimizing various factors (such as fluid velocity, sample concentration, reaction time, reaction temperature, etc.) through experiments to improve the sensitivity, specificity and stability of the test strip.

[0061] Furthermore, the test strips were verified by using serum samples containing different concentrations of the liver cancer marker AFP to verify the accuracy and repeatability of the test strips, as well as their performance in actual samples.

[0062] In this way, a lateral flow test strip for early diagnosis of liver cancer is obtained.

[0063] Furthermore, the distance between the binding pad and the detection line is 8-30 mm.

[0064] Based on the above technical solution, the present invention achieves the following technical effects: 1. The test paper of the present invention has the advantages of high efficiency, rapidity, convenience and accuracy. It does not require professional operation, and ordinary people can complete the test work. The test result can be obtained in just 15 minutes.

[0065] 2. The present invention screens a pair of nucleic acid aptamers A and B targeting the liver cancer target AFP, fixes A on the surface of nanogold, fixes B on the detection line, and uses lateral flow technology to identify samples containing AFP markers. BRIEF DESCRIPTION OF THE DRAWINGS

[0066] Figure 1 This is a photo of nucleic acid gel analysis after nucleic acid aptamer screening.

[0067] Figure 2 This is a photo of the BLI affinity test results. As can be seen from the figure, as the concentration of the aptamer increases, the affinity increases in a gradient.

[0068] Figure 3 This is a photo of the affinity test result of biotinylated apt30. As can be seen from the figure, the kd value of aptamer apt30 for AFP is 1.099 x10 -8 Mol, and R 2 >0.5.

[0069] Figure 4 This is the secondary structure analysis diagram of three nucleic acid aptamers: apt1, apt17, and apt30.

[0070] Figure 5 It is a schematic diagram of the basic principle of lateral flow test strip design.

[0071] Figure 6 Schematic diagram of the principle of aptamer-based detection of AFP in hepatocellular carcinoma tissue sections. DETAILED DESCRIPTION

[0072] The technical solution of the present invention is explained below in conjunction with specific cases, which is only to help better understand the technical solution of the present invention, and is not intended to limit the scope of the solution of the present invention. It should be understood that all inventions based on the same concept are within the scope of protection required by the present invention.

[0073] Example 1 Aptamer screening The first step is to unwind the DNA double helix to denature the DNA: Design of initial library sequence: The total length of the initial library of biolayer interference SELEX is 76 nt, and the sequence is as follows: 5′-ATCCAGAGTGACGCAGCANNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNTGGACACGGTGGCTTAGT-3′; where N represents any base among A, T, C, and G, and there are 40 N in total.

[0074] Using the resources of an external commercial nucleic acid sequence synthesis company (Shanghai, China), nucleic acid crystals of the initial library sequence were synthesized. The initial library size was 10 14 .

[0075] 2OD synthetic nucleic acid crystals provided by Bio-Tech were directly added to 200 μL PBST (Tween 20-phosphate buffer, pH=7.4) for dissolution. Dissolution was performed at 95°C for 10 minutes, and the three-dimensional structure of the aptamer was denatured, losing its original structure and dissociating it to obtain a nucleic acid aptamer solution.

[0076] Step 2: Rapidly renature the DNA double helix: After dissociation is completed, immediately place the nucleic acid aptamer solution from the first step in ice and cool for 10 minutes to allow the nucleic acid aptamer to quickly refold and re-form functional secondary and tertiary spatial conformations to ensure the stability and activity of the aptamer.

[0077] Step 3: Stabilize the renatured aptamers: Then, the refolded aptamers in step 2 were incubated at 37°C for 1 hour to obtain an aptamer solution. 50 μL of aptamers were diluted with 150 μL of PBST to prepare an oligomer pool.

[0078] Step 4, probe screening: Purchase AFP protein with HIS tag from a biological reagent company, use a 96-well plate, add 195μL PBST and 5μL of the AFP protein, a total of 200μL liquid, as the AFP protein reaction pool. After the nickel probe of the NI-NTA (nickel-trinitroacetic acid) sensor is activated with PBST for 10 minutes, the nickel probe based on the NI-NTA sensor is loaded into the AFP protein reaction pool and kept for 600 seconds, so that the AFP protein with His tag is loaded onto the probe.

[0079] Then, the AFP protein that is not firmly bound to the nickel probe is washed away, and then it is allowed to bind to the nucleic acid aptamers in the oligomer pool respectively. The binding curve is seen to rise through the BLI instrument Octet® Red96 system (FortéBio). The system is then rinsed twice with 200 μL of PBST for 480 seconds each time to remove the weakly bound nucleic acid aptamers and improve the purity of the screening.

[0080] Step 5: Cutting the aptamer: Take two 1.5 mL EP tubes, aspirate the PBST-aptamer solution under the nickel probe (NI-NTA sensor), and place the corresponding probes in two EP tubes, all next to an alcohol lamp. Then, add 1.8 μL of proteinase K (purchased from Sigma, a strong proteinase) to each of the two EP tubes, and place them in a 52°C water bath for 1 hour. Proteinase K is used to cut the aptamer and degrade exogenous contaminants in the aptamer, exposing the site sequence where the aptamer binds to the AFP protein.

[0081] Step 6. Terminate the proteinase K reaction: Then, place the EP tube containing the nucleic acid aptamer in a 95°C water bath and degrade it for 10 minutes. After the reaction is completed, place it at room temperature for use.

[0082] Step 7, PCR reaction: operate under sterile conditions, take two 0.5mL EP tubes (sterilized), add 25μL of TaqDNA polymerase (purchased from Bio-Technology Co., Ltd.), add 20μL of the degraded nucleic acid aptamer obtained in step 6, and 2μL of primer 1 (purchased from Bio-Technology Co., Ltd.) and primer 2 (purchased from Bio-Technology Co., Ltd.). Then, add sterilized ddH2O to obtain a total of 50μL system, put it in the middle of the PCR instrument, ensure uniform heating, set parameters (95℃ 3 minutes; 95℃ 20 seconds; 60℃ 15 seconds; 72℃ 15 seconds; 50 repeated cycles; 72℃ 5 minutes; stored at 4℃), PCR for about 1 hour and 35 minutes. Note that Taq DNA polymerase (Bio-Technology Co., Ltd.) contains dATP, dCTP, dGTP and dTTP, and the proportions have been prepared.

[0083] The sequence of primer 1 is ACTAAGCCACCGTGTCCA, which was purchased from Bio-Technology Co., Ltd.

[0084] The sequence of primer 2 is: ATCCAGAGTGACGCAGCA, which was purchased from Biotechnology Co., Ltd.

[0085] Step 8: Run the aptamer gel: After the PCR reaction in step 7 is completed, the reaction product is run on a nucleic acid gel using 0.3 wt% agarose and a nucleic acid stain is added. The staining results are shown in Figure 1. Figure 1 shown.

[0086] Step 9. Purification of nucleic acid aptamers: Check the corresponding marker bands to confirm that the obtained nucleic acid aptamers are target nucleic acid aptamers and are not contaminants. Then, use FastPure® Gel DNA Extraction Mini Kit (Nanjing Novogene Biotech Co., Ltd.) to purify the nucleic acid aptamers according to the instructions.

[0087] The general steps are as follows: Set the water bath temperature to 50-55°C in advance. Add 100 μL of sol to 100 mg of PCR reaction solution, put it in a water bath, add 300 μL of Buffer GDP, 700 μL of Buffer GW, add 700 μL of Buffer GW, combine, wash; then, add 20-30 μL of Elution Buffer or ddH2O for elution.

[0088] Step 10. Measure the concentration of nucleic acid aptamers after running the gel: Use NanoDrop One / OneC micro-volume nucleic acid protein concentration meter to measure the concentration of nucleic acid aptamers and A260 / A280, A260 / A230; all are within the normal range.

[0089] illustrate: The absorbance of the aptamer at 260 nm and 280 nm was measured to obtain A260 and A280, respectively. The A260 / A280 ratio was calculated to evaluate the purity of the aptamer sample. The results showed that the A260 / A280 ratio was between 1.8 and 2.0, which was within the normal range.

[0090] Similarly, the absorbance of the aptamer at 260nm and 230nm is measured, and the A260 / A230 ratio is calculated to evaluate the purity of the nucleic acid sample, which is used to detect salts and small molecule contaminants in the sample (A230 reflects the absorbance of salts and small molecule impurities in the solution). The index for evaluating the purity of nucleic acid samples, the result of A260 / A230 ratio greater than 2.0, indicates that there are no contaminants in the aptamer sample.

[0091] Step 11: Use the nucleic acid aptamers purified in step 9 of the previous round as the nucleic acid raw material for the next round of screening (replacing the nucleic acid crystals of the initial library in step 1), and then repeat steps 1 to 10 for a total of 10 screenings, and save the results of each screening.

[0092] Starting from the third round, in the fourth step of probe screening, human serum with dilutions of 10, 8, 6, 4, 2, and 0 times was used to interfere with the binding process between nucleic acid aptamers and AFP protein. In the fourth step of probe screening in the eighth round of screening, the concentration of AFP was reduced to 1 / 3 of that in the first round.

[0093] Step 12: Sequencing: The purified results from the last PCR in the 7th and 10th rounds (corresponding to the product in the 9th step) were commissioned to Sangon (Shanghai, China) for sequencing.

[0094] Step 13. Data analysis: Use the web-based nucleic acid sequence analysis software BioLadder (www.bioladder.cn / web / ) or BIORUN (www.biorun.com) to analyze the secondary and tertiary structures of the obtained nucleic acid aptamers.

[0095] The chemical bonds and groups of the interaction between the obtained aptamer and alpha-fetoprotein were analyzed by browsers such as PLIP Web, and molecular simulation was performed. The docking of the two was analyzed, and then the molecular docking diagram between AFP alpha-fetoprotein and aptamer DNA was analyzed intuitively by Pymol software from Schrödinger.

[0096] A total of the first 54 sequencing results were analyzed, and the top 20 nucleic acid aptamers with the lowest energy (kd value) were selected, and Sangon (Shanghai, China) was again commissioned to perform base sequence synthesis.

[0097] Step 14: BLI sensor measures kd value and affinity measurement: Referring to the method in step 4, load the His-tagged alpha-fetoprotein (AFP) onto the nickel-probe for 600 seconds. Then, according to the suggestions of the sequencing company, dilute the synthesized nucleic acid aptamer to a concentration of 10 umol / L with PBST, place it in a 95℃ water bath for 10 minutes to fully denature, and then immediately place it in -20℃ to cool for 10 minutes, and then place it in a 37℃ water bath for 1 hour for standby use.

[0098] Aptamer reaction pool: Take a 96-well plate and use PBST and the aptamers of the synthesis results of the 20 aptamers selected after the thirteenth step analysis to prepare a 200 μL system (PBST 150 μL, aptamer 50 μL).

[0099] Then, PBST was used to dilute the solution to different concentrations according to the concentration gradient of 0, 2, 4, 6, and 8 to obtain nucleic acid aptamer reaction pools of different concentrations. The affinity was measured using probes loaded with AFP in nucleic acid aptamer reaction pools of different concentrations. The results are shown in Figure 2. Figure 2 As shown, by observing the curve changes of Data Acquisition 11.1 software, it can be clearly seen that as the concentration of nucleic acid aptamers increases, the curve of AFP binding to nucleic acid aptamers rises accordingly and forms a certain gradient change.

[0100] Finally, the Data Analysis HT data analysis system was used to analyze the kd value (dissociation rate constant) of AFP and nucleic acid aptamers, and the kd value of 10 -8 The nucleic acid aptamers with a molecular weight below 100 were selected, and the reliability R 2 All of them are greater than 0.5, which is in line with the expected assumption.

[0101] Step 15: Octet® Streptavidin (SA) biosensor to screen the best nucleic acid aptamer: Combining the kd value obtained by BLI measurement in step 14, the tertiary structure of the aptamer, and the energy table of docking with the alpha-fetoprotein (AFP) protein mimic molecule, 6 aptamers with the lowest binding energy were screened out and commissioned to Biotech to modify the 5' end of the aptamer with biotinylation.

[0102] Then, using a streptavidin (SA) biosensor, the modified aptamer was loaded onto the SA-probe of the streptavidin biosensor, and rinsed with 200 μL of phosphate buffer (PBST buffer) containing Tween-20 for 80 seconds to remove the aptamer that was not bound to the SA-probe. The phosphate buffer containing Tween-20 is a colorless liquid with a pH of 7.4. The commercial PBST concentrate was purchased and diluted with deionized water before use.

[0103] The streptavidin (SA, molecular weight ≈ 65 kDa, isoelectric point ≈ 6.0) used is a secretory protein extracted from the culture of Streptomyces Avidinii. Streptavidin is a tetrameric protein and a biotin-binding protein that contains four subunits, each with a biotin binding site. In the experiment, a commercial version of streptavidin (SA, manufacturer: Thermo Fisher Scientific) was used.

[0104] Then, it is combined with AFP (aptamer concentration is 0.0214nmol / L) in the aptamer reaction pool to measure its affinity and obtain the kd value. When dissociating, part of the AFP is bound to the probe and not dissociated, indicating that the binding is strong. Finally, the kd value is measured twice in the same way to improve repeatability.

[0105] Finally, the Data Analysis HT data analysis system was used to analyze the kd value of AFP and biotinylated nucleic acid aptamers, and the kd value was less than 10 -9 mmol / L, nucleic acid aptamers with better affinity, and at the same time taking into account R 2 All of them were greater than 0.5, which was in line with the expected assumption. The three nucleic acid aptamer sequences with the highest affinity were finally determined to be aptamer30>aptamer17>aptamer1.

[0106] The obtained sequences of aptamer1, aptamer17, and aptamer30 (abbreviated as apt1, apt17, and apt30) are as follows, in order: apt1 sequence: CACCCACCATACACCCTGTCCACATGCCTGACCTCATGCG.

[0107] apt17 sequence: CCAACCGCATGACGAGGCTATGGGACACTTGCCCTGCCCG.

[0108] apt30 sequence: CCACAGTCCGGACCCCACGTTGCTACCGGCGCCGTCG.

[0109] Among them, the affinity determination results of apt30 with the best activity are as follows Figure 3 shown.

[0110] Furthermore, the secondary structure of the three aptamers with the best activity, apt1, apt17, and apt30, was analyzed. Figure 4 As shown in the figure, the secondary structure analysis diagram of apt30 nucleic acid aptamer has two ring structures, which are the key to capture AFP protein.

[0111] The correspondence between the 5' and 3' ends of the apt1 sequence is: 5'-CACCCACCATACACCCTGTCCACATGCCTGACCTCATGCG-3'.

[0112] The correspondence between the 5' and 3' ends of the apt17 sequence is: 5'-CCAACCGCATGACGAGGCTATGGGACACTTGCCCTGCCCG-3'.

[0113] The corresponding situation of the 5' and 3' ends of the apt30 sequence is 5'-CCACAGTCCGGACCCCACGTTGCTACCGGCGCCGTCG-3'.

[0114] Example 2 On the basis of Example 1, specificity verification and clinical application research of nucleic acid aptamers aptamer1, aptamer17 and aptamer30 were conducted, and the specific methods are as follows.

[0115] AFP specificity verification: The three aptamer sequences aptamer1, aptamer17, and aptamer30 obtained in Example 1 were respectively bound to the SA-probe, and washed with 200 μL of PBST buffer for 80 seconds to remove the unbound aptamers. Then, the aptamers were reacted and dissociated in a reaction pool containing 200 μL of normal human serum containing AFP, and the screened aptamers were observed to specifically bind to AFP. The experimental results showed that the screened aptamers could specifically bind to AFP.

[0116] Example 3 In order to further verify the nucleic acid aptamers screened by the present invention, a validation study on nucleic acid aptamers for detecting tumor cells was conducted. The nucleic acid aptamers (aptamer1, aptamer17, aptamer30) with high affinity for AFP obtained by screening in Example 1 were used to replace the widely used antibodies in clinical practice to label AFP in pathological tissues of malignant tumors such as liver cancer and germ cell tumors, thereby realizing rapid, accurate and low-cost detection of AFP in pathological tissues.

[0117] like Figure 6 The figure shows the detection principle of tumor marker AFP based on aptamer.

[0118] First, prepare liver cancer pathological tissue sections according to the standardized pathological specimen processing process, including: sampling, fixing with 10% formalin solution for 24 hours, diluting with low to high concentrations of anhydrous ethanol, transparentizing with xylene, waxing with heated paraffin, embedding with melted paraffin, cutting tissue slices of about 0.3-0.5CM, spreading in a warm water bath, and placing on a slide for antigen repair. Then, add the pre-treated nucleic acid aptamer and perform a staining reaction. The general design of the experiment is shown in the figure below. Figure 5 As shown, rapid, accurate and low-cost detection of AFP in malignant tumor tissues such as liver cancer can be achieved.

[0119] like Figure 5 The basic principle of the nanogold colloid test strip is shown to prepare a lateral flow test strip for early diagnosis of liver cancer.

[0120] S1 Preparation of colloidal gold nanoparticle complex: The nucleic acid aptamers apt30, apt17, and apt1 obtained in Example 1 are bound to gold nanoparticles to construct a nucleic acid aptamer gold nanoparticle complex.

[0121] Taking apt17 as an example, the specific method for constructing the nucleic acid aptamer gold nanoparticle complex is as follows: connect three thymines to the 5' end of apt17, and then combine the thymines and gold nanoparticles (Au NP) through the thiol group to obtain the Au NP-poly T peptide chain-aptamer apt17 complex for use as a detection reagent. apt17 is connected to the gold nanoparticles through the thiol group and added to the conjugate pad as colloidal gold.

[0122] Correspondingly, the quality control line (C line) is set to fix the poly A peptide chain (C sequence), and the adenine oligopeptide chain is: -AAAAAAAAA-. The adenine oligopeptide chain is connected to three thymine Ts at the 5 ends of the aptamer to form a complementary sequence. The quality control line can capture the aptamer that reacts to the detection line and verify that the detection reaction is complete.

[0123] S2 Preparation of test strips: Design lateral flow test strips, which consist of four parts: sample suction pad, conjugate pad, reaction pad and adsorption pad. Coat the antibody-gold nanoparticle complex on the conjugate pad, and prepare various test lines and control lines on the reaction pad. Finally, connect the parts in sequence to form a complete test strip.

[0124] Verify the clinical sensitivity of the test strip: Use serum samples containing different concentrations of liver cancer markers to verify the accuracy and feasibility of the test strip and evaluate whether it can be used in the field. Serum samples containing liver cancer marker AFP protein were removed separately, and serum samples with AFP protein concentrations of 5 ng / mL, 10 ng / mL, 20 ng / mL, and 50 ng / mL were obtained after dilution. They were added to the above-mentioned lateral flow test strips for detection. Results The sensitivity of the on-site test strips was good, and it could accurately identify serum samples ≥5 ng / mL.

[0125] Furthermore, the clinical sensitive test strips for AFP detection prepared by lateral flow chromatography were verified. The reactant (serum sample) of the subject was diluted to 50% concentration with PBST and then dripped onto the sample pad of the test strip, and then the results were observed. For subjects with positive test strips, further examinations were conducted in the hospital to confirm the diagnosis and verify the reliability of the results.

[0126] During the experiment, a total of 10 subjects participated in the experiment, and 6 subjects tested positive by lateral flow test strips. Five patients were further diagnosed with liver cancer after further examination at the hospital. Therefore, the accuracy of the clinical sensitive test strips for detecting AFP was 100%. The results of the hospital's pathological section test review showed that the accuracy of nucleic acid aptamers in detecting liver cancer tumor cells was 83.3%. Note that the experimental samples are small, and the research scope needs to be further expanded to improve the accuracy and reliability of the research results.

Claims

1. A nucleic acid aptamer for detecting tumor marker AFP, characterized in that: The sequence of the nucleic acid aptamer is at least one of apt30, apt17 or apt1.

2. The nucleic acid aptamer according to claim 1, characterized in that The sequence of apt30 is SEQ NO.

3.

3. The nucleic acid aptamer according to claim 1, characterized in that The sequence of apt17 is SEQ NO.

2.

4. The nucleic acid aptamer according to claim 1, characterized in that The sequence of apt1 is SEQ NO.

1.

5. The nucleic acid aptamer according to any one of claims 2 to 4, characterized in that: The 5' end of the nucleic acid aptamer is connected to thymine -TTT-.

6. A lateral flow test strip for detecting tumor marker AFP based on aptamer specificity, characterized in that: The lateral flow test strip comprises a PVC bottom plate, a sample suction pad, a conjugation pad, a reaction pad and an adsorption pad; the sample suction pad, the conjugation pad, the reaction pad and the adsorption pad are sequentially arranged on the PVC bottom plate and are connected to each other without gaps; The reaction pad is provided with a detection line and a quality control line; The binding pad is provided with a gold nanoparticle complex binding to a nucleic acid aptamer A, wherein the sequence of the nucleic acid aptamer A is one of SEQ NO.1, SEQ NO.2 or SEQ NO.3; The detection line is provided with a nucleic acid aptamer B, the sequence of the nucleic acid aptamer B is selected from one of SEQ NO.1, SEQ NO.2 or SEQ NO.3, and the nucleic acid aptamer B and the nucleic acid aptamer A are different sequences; The quality control line is provided with a complementary sequence polyadenine or anti-human immunoglobulin.

7. A lateral flow test strip for detecting tumor marker AFP based on aptamer specificity according to claim 6, characterized in that: The sample suction pad, the binding pad, the reaction pad and the adsorption pad are arranged in sequence, and adjacent ones are overlapped and connected.

8. A lateral flow test strip for detecting tumor marker AFP based on aptamer specificity according to claim 7, characterized in that: The overlap width is 0.1-3 mm, and the distance between the detection line and the quality control line on the reaction pad is set to 3-30 mm.

9. A lateral flow test strip for detecting tumor marker AFP based on aptamer specificity according to claim 6, characterized in that: The preparation method of the binding pad is as follows: connecting the nucleic acid aptamer A to the gold nanoparticles to form a nucleic acid aptamer A gold nanoparticle complex, and coating the nucleic acid aptamer A gold nanoparticle complex on the binding pad; then, setting a detection line and a quality control line on the reaction pad.

10. A lateral flow test strip for detecting tumor marker AFP based on aptamer specificity according to claim 9, characterized in that: The gold nanoparticle complex bound to nucleic acid aptamer A is obtained by connecting three thymines to the 5' end of nucleic acid aptamer A, and then connecting the thymines and gold nanoparticles via thiol groups.